Related Experiment Video

Updated: Aug 9, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Epidermal growth factor receptor inhibitors in cancer treatment

Fortunato Ciardiello1

  • 1Cattedra di Oncologia Medica, Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A. Lanzara, Seconda Università degli Studi di Napoli, Via S. Pansini 5, 80131 Napoli, Italy. fortunato.ciardiello@unina2.it

Future Oncology (London, England)
|March 25, 2006
PubMed

Insights

Targeting the epidermal growth factor receptor (EGFR) offers a promising approach in cancer therapy. This review details the clinical development of anti-EGFR drugs like Cetuximab and Gefitinib for various cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The epidermal growth factor receptor (EGFR) is a key regulator of cell proliferation, apoptosis, and angiogenesis, frequently implicated in human cancer.
  • Dysregulation of EGFR signaling pathways contributes to cancer development and progression, making it a significant therapeutic target.
  • Targeting EGFR represents a crucial molecular strategy in modern cancer treatment.

Purpose of the Study:

  • To review the preclinical and clinical data of anti-EGFR drugs in advanced stages of development.
  • To discuss the current landscape and future directions for EGFR-targeted cancer therapies.
  • To highlight open clinical issues and strategies for optimizing the use of EGFR-targeting agents.

Main Methods:

  • Review of preclinical studies on EGFR function and targeted agents.
  • Analysis of clinical trial data for approved and investigational anti-EGFR drugs.
  • Discussion of therapeutic strategies involving EGFR inhibitors in various cancer types.

Main Results:

  • Cetuximab (Erbitux), an EGFR monoclonal antibody, is approved for refractory colorectal cancer.
  • Gefitinib (Iressa), a small molecule EGFR inhibitor, is approved for chemoresistant non-small cell lung cancer.
  • Several anti-EGFR drugs are in Phase III clinical trials, used alone or in combination therapies.

Conclusions:

  • Targeting the EGFR is a validated and evolving strategy in cancer therapy.
  • The clinical development of anti-EGFR drugs like Cetuximab and Gefitinib has shown significant promise.
  • Further research is needed to optimize treatment strategies and address clinical challenges for EGFR-targeted agents.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...